Basis: FMP quote price / unrounded FMP forward EPS in the trading currency, available after its recorded retrieval time. Source: stored company filings and market data; unavailable inputs remain N/A.
The forward PE ratio is N/A as of 2026-10-06T17:36:53.740Z.
Consensus retrieved: 2026-10-06T12:40:20.345Z. This records retrieval, including cache reads, rather than vendor publication. The calculation uses the separately dated price and estimate available at its as-of time.
Calculation as of: 2026-10-06T17:36:53.740Z.
Quote observation: 2026-10-06T17:35:01.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: a840c676881d241076febf00b391d6b63dc7604cd07ac1d060a0848db02ea459
Forward PE Ratio (N/A) = Dated Quote Price ($1.99) / Consensus Forward EPS ($-0.45)
FORWARD PE RATIO
N/A
Inhibikase Therapeutics, Inc.
Market Cap
$262.75M
Forward PE Ratio
N/A
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| Inhibikase Therapeutics, Inc. (IKT) | $262.75M | N/A |
| Eupraxia Pharmaceuticals Inc. (EPRX)vs › | $262.65M | N/A |
| EyePoint Pharmaceuticals, Inc. (EYPT)vs › | $262.84M | N/A |
| OraSure Technologies, Inc. (OSUR)vs › | $263.69M | N/A |
| Palisade Bio, Inc. (PALI)vs › | $260.37M | N/A |
| X4 Pharmaceuticals, Inc. (XFOR)vs › | $259.85M | N/A |
| TriSalus Life Sciences, Inc. (TLSI)vs › | $266.00M | N/A |
| Lexeo Therapeutics, Inc. Common Stock (LXEO)vs › | $258.39M | N/A |
| AC Immune S.A. (ACIU)vs › | $256.98M | N/A |
| Treace Medical Concepts, Inc. (TMCI)vs › | $268.57M | N/A |
Trailing P/E
N/A
reported TTM EPS
Forward P/E
N/A
consensus EPS · fiscal year ending 2026-12-31
At the dated quote price of $1.99, each upcoming fiscal year's consensus EPS implies a different multiple — how quickly the price is "paid down" by expected earnings if the estimates hold.
| Fiscal year end | Consensus EPS | Estimate range | Analysts | Implied P/E |
|---|---|---|---|---|
| 2026-12-31 | $-0.45 | $-0.53 – $-0.40 | 5 | n/m |
| 2027-12-31 | $-0.47 | $-0.50 – $-0.41 | 5 | n/m |
| 2028-12-31 | $-0.40 | $-0.57 – $-0.22 | 5 | n/m |
Source: FMP analyst consensus estimates, refreshed with the daily precompute. "n/m" = the consensus EPS is not positive, so a multiple is undefined. There is no forward P/E history chart here because charting one would require the estimates as they stood in the past, which we do not store — see the trailing P/E history for how the realized multiple has moved.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
